Guidance on the use of riluzole (Rilutek) for the treatment of motor neurone disease

To enable clinicians to audit their own compliance with this guidance, it is recommended that treatment plans are recorded for each patient.

This information should be incorporated into local audit data recording systems and consideration given (if not already in place) to the establishment of appropriate categories in routine electronic record-keeping systems used in hospitals and the multidisciplinary groups working in support of people with motor neurone disease (MND).

Relevant guidelines and protocols linking the multidisciplinary working for people with MND should be reviewed in the light of this guidance.

Prospective clinical audit programmes should record the proportion of treatments adhering to this guidance. Such programmes are likely to be more effective in improving patient care when they form part of the organisation's formal clinical governance arrangements and where they are linked to specific post-graduate activities.